CO2023009279A2 - Moléculas de unión a gucy2c y sus usos - Google Patents
Moléculas de unión a gucy2c y sus usosInfo
- Publication number
- CO2023009279A2 CO2023009279A2 CONC2023/0009279A CO2023009279A CO2023009279A2 CO 2023009279 A2 CO2023009279 A2 CO 2023009279A2 CO 2023009279 A CO2023009279 A CO 2023009279A CO 2023009279 A2 CO2023009279 A2 CO 2023009279A2
- Authority
- CO
- Colombia
- Prior art keywords
- gucy2c
- binding molecules
- chimeric antigen
- antigen receptors
- lymphocytes
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 abstract 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 abstract 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01002—Guanylate cyclase (4.6.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan anticuerpos de dominio simple que se unen a GUCY2C y receptores de antígenos quiméricos que los comprenden. Además se proporcionan células efectoras inmunitarias modificadas (tales como linfocitos T) que comprenden los receptores de antígenos quiméricos. También se proporcionan composiciones farmacéuticas, kits y métodos para tratar una enfermedad o trastorno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020137164 | 2020-12-17 | ||
PCT/CN2021/138845 WO2022127871A1 (en) | 2020-12-17 | 2021-12-16 | Gucy2c binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023009279A2 true CO2023009279A2 (es) | 2023-07-21 |
Family
ID=82060074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0009279A CO2023009279A2 (es) | 2020-12-17 | 2023-07-13 | Moléculas de unión a gucy2c y sus usos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240059794A1 (es) |
EP (1) | EP4263615A1 (es) |
JP (1) | JP2023554467A (es) |
KR (1) | KR20230131183A (es) |
CN (1) | CN116917329A (es) |
AU (1) | AU2021404641A1 (es) |
BR (1) | BR112023011658A2 (es) |
CA (1) | CA3205007A1 (es) |
CL (1) | CL2023001665A1 (es) |
CO (1) | CO2023009279A2 (es) |
CR (1) | CR20230245A (es) |
EC (1) | ECSP23053774A (es) |
IL (1) | IL303610A (es) |
MX (1) | MX2023006969A (es) |
WO (1) | WO2022127871A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027815A1 (zh) * | 2022-08-05 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 特异性结合gucy2c和cd3的抗原结合分子及其医药用途 |
CN116751303B (zh) * | 2022-12-09 | 2023-12-26 | 华道(上海)生物医药有限公司 | 一种抗鸟苷酸环化酶2c的纳米抗体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156915B2 (en) * | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
ES2749181T3 (es) * | 2012-04-27 | 2020-03-19 | Millennium Pharm Inc | Moléculas de anticuerpo anti-GCC y uso de las mismas para ensayar la susceptibilidad a una terapia dirigida a GCC |
BR112020013244A2 (pt) * | 2018-01-04 | 2020-12-01 | Shanghai Lumosa Therapeutics Co., Ltd. | proteínas de fusão de anticorpo citosina-desaminase de domínio único |
TWI816396B (zh) * | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | 特異性針對gucy2c之抗體及其用途 |
-
2021
- 2021-12-16 CA CA3205007A patent/CA3205007A1/en active Pending
- 2021-12-16 US US18/265,779 patent/US20240059794A1/en active Pending
- 2021-12-16 CN CN202180093966.2A patent/CN116917329A/zh active Pending
- 2021-12-16 JP JP2023537253A patent/JP2023554467A/ja active Pending
- 2021-12-16 IL IL303610A patent/IL303610A/en unknown
- 2021-12-16 AU AU2021404641A patent/AU2021404641A1/en active Pending
- 2021-12-16 BR BR112023011658A patent/BR112023011658A2/pt unknown
- 2021-12-16 CR CR20230245A patent/CR20230245A/es unknown
- 2021-12-16 MX MX2023006969A patent/MX2023006969A/es unknown
- 2021-12-16 EP EP21905797.3A patent/EP4263615A1/en active Pending
- 2021-12-16 WO PCT/CN2021/138845 patent/WO2022127871A1/en active Application Filing
- 2021-12-16 KR KR1020237020647A patent/KR20230131183A/ko unknown
-
2023
- 2023-06-08 CL CL2023001665A patent/CL2023001665A1/es unknown
- 2023-07-13 CO CONC2023/0009279A patent/CO2023009279A2/es unknown
- 2023-07-17 EC ECSENADI202353774A patent/ECSP23053774A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN116917329A (zh) | 2023-10-20 |
MX2023006969A (es) | 2023-08-25 |
CL2023001665A1 (es) | 2024-01-12 |
CR20230245A (es) | 2023-09-01 |
WO2022127871A1 (en) | 2022-06-23 |
KR20230131183A (ko) | 2023-09-12 |
IL303610A (en) | 2023-08-01 |
CA3205007A1 (en) | 2022-06-23 |
ECSP23053774A (es) | 2023-09-29 |
EP4263615A1 (en) | 2023-10-25 |
JP2023554467A (ja) | 2023-12-27 |
AU2021404641A1 (en) | 2023-06-29 |
US20240059794A1 (en) | 2024-02-22 |
BR112023011658A2 (pt) | 2023-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023009279A2 (es) | Moléculas de unión a gucy2c y sus usos | |
CO2019000946A2 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CL2012002329A1 (es) | Molecula de anticuerpo quimerico que se une a cd37 humano; molecula de adn que codifica la cadena pesada y la cadena liviana de las regiones variables del anticuerpo; vector de expresion y celula huesped que comprende dichos adn; composicion farmaceutica que comprende los anticuerpos; uso de la composicion en la supresion de celulas b (divi. sol. 2349-08) | |
UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
CL2023000896A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
CR11783A (es) | Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno | |
CL2021002586A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
CL2011000117A1 (es) | Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende. | |
CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
CO2021016907A2 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
CL2019000999A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
AR120222A1 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
AR112770A1 (es) | Anticuerpos anti-ctla-4 y sus usos | |
CO2023013550A2 (es) | Polipéptido de unión a gucy2c y usos del mismo | |
AR117578A1 (es) | Anticuerpos específicos para cd3 y sus usos | |
AR102714A1 (es) | Terapia combinada de moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje pd-1 | |
AR113469A1 (es) | Receptores de antígenos quiméricos específicos para el antígeno de maduración de células b y polinucleótidos que codifican los mismos |